

Review

Use of Replicating Oncolytic Adenoviruses in Combination Therapy for Cancer

Roland L. Chu,^{1,2} Dawn E. Post,¹
Fadlo R. Khuri,¹ and Erwin G. Van Meir¹

¹Laboratory of Molecular Neuro-Oncology, Departments of Neurosurgery, Hematology/Oncology, and Winship Cancer Institute, and ²AFLAC Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Emory University, Atlanta, Georgia

ABSTRACT

Oncolytic virotherapy is the use of genetically engineered viruses that specifically target and destroy tumor cells via their cytolytic replication cycle. Viral-mediated tumor destruction is propagated through infection of nearby tumor cells by the newly released progeny. Each cycle should amplify the number of oncolytic viruses available for infection. Our understanding of the life cycles of cytolytic viruses has allowed manipulation of their genome to selectively kill tumor cells over normal tissue. Because the mechanism of tumor destruction is different, oncolytic virotherapy should work synergistically with current modes of treatment such as chemotherapy and radiation therapy. This article focuses on oncolytic adenoviruses that have been created and tested in preclinical and clinical trials in combination with chemotherapy, radiation therapy, and gene therapy.

INTRODUCTION

Cancer remains one of the top causes of death in adults and children. Progress has been made in the overall survival of cancer patients after the emergence of better imaging and diagnostic techniques, improved understanding of the molecular processes that cause cancer, and additional knowledge of treatment using combined chemo- and radiotherapy. However, survival has not improved with current chemotherapy and radiation regimens in patients diagnosed with metastatic disease and certain tumors such as malignant neoplasms of the brain, pancreas, and liver. This is usually due to tumor cells developing genetic mechanisms that override apoptosis caused by chemo-

therapy and radiation damage to their DNA. This confers resistance to treatment through clonal expansion of genetically resistant tumor cells. Much effort has been directed toward finding alternate pathways that would complement therapeutic induction of apoptosis, overcome multidrug resistance, and ultimately improve overall cure rates. Although the dream of developing a single curative drug per cancer type drives the field, the reality is that combination therapy will be the most effective way of improving survival.

The use of viruses that specifically kill tumor cells while sparing normal cells, known as oncolytic virotherapy, has re-emerged over the past 7 years (1, 2). Viruses have evolved to maximize their ability to enter cells, use the machinery of the host cell to replicate and package their own genome and lyse the cells to release their progeny and propagate the viral replicative cycle. Wild-type viruses have been discovered that have tumor-specific cytolysis, such as Newcastle disease virus, vesicular stomatitis virus, vaccinia virus, reovirus, and autonomous parvovirus (3). Furthermore, with the advances of molecular biology and understanding the function of viral genes, it has become possible to genetically re-engineer other viruses to make them selectively target tumor cells. Much of this work has been carried on in adenoviruses and herpesviruses (4, 5), which can also function as therapeutic gene delivery vehicles.

Several biological features have made the adenovirus an attractive virus for oncolytic virotherapy. It is a common pathogen. Viral replication leads to host cell destruction, and a 1000-fold amplification of the viral load is achieved in a single replicative cycle, allowing spread of viral infection. Another biological feature that makes adenoviruses attractive for cancer therapy is that high-titer viral stocks (10^{10} plaque-forming units/ml) can be produced, which can then be additionally concentrated 100-fold. The viral genome does not integrate into the cell genome, so the risk of recombination and mutation is low. The genome is also large enough to accommodate the incorporation of foreign genes. The technology to manipulate the viral genome is also readily available so that recombinant adenoviruses can be made tumor selective.

This review will describe the mechanisms by which oncolytic adenoviruses that target cancer cells have been designed and their use in combination with chemotherapy, radiation therapy, and gene therapy including the results of clinical trials.

ADENOVIRUS BIOLOGY

Over 40 different serotypes of adenoviruses have been discovered with serotypes 2 and 5 being the most extensively used in developing oncolytic adenoviruses. These viruses primarily infect the epithelial tissue lining the respiratory tract. The most common symptoms are mild upper respiratory symptoms such as nasal congestion and rhinorrhea (runny nose), cough, and conjunctivitis. Adenovirus (type 2 and 5) infection occurs

Received 3/10/03; revised 3/11/04; accepted 3/12/04.

Grant support: Support is given to the Van Meir laboratory by the NIH (Grants CA87830, NS41403-01 NS049300-01), the C. Geyer Foundation, and the Brain Tumor Society.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Note: R. L. Chu and D. E. Post should be considered first coauthors.

Requests for reprints: Erwin G. Van Meir, Winship Cancer Institute, Emory University, 1365-C Clifton Road N.E., Room C5078, Atlanta, GA 30322. Phone: (404) 778-5563; Fax: (404) 778-5240; E-mail: evanmei@emory.edu.

through binding of the adenoviral fiber to cellular receptors such as the coxsackie-adenovirus receptor or integrins. Once bound, the virus is internalized via receptor-mediated endocytosis and brought to the nucleus. During transport, disassembly of the viral capsid takes place allowing the viral DNA to enter through the nuclear pores. Once the viral genome enters the nucleus, viral transcription begins.

Adenoviral transcription occurs in three phases: early, intermediate, and late (6). During the early phase, the host cell is transformed into an efficient producer of the viral genome. Because most cells are in a quiescent state, viral proteins must interact with the proteins of the host cell to activate cell replication and division. The first gene that is transcribed in the viral genome is *E1A*, and its product binds with many cellular proteins such as the pRb, p107, and p130 family of proteins. This interaction prevents these cellular proteins from blocking E2F transcription factors, leading to the initiation of DNA replication and the cell cycle (7). Because the E1A protein will activate the cellular repair or apoptotic pathway mediated by p53-dependent and independent pathways, expression of the adenoviral *E1B* gene products prevents early death of the host cell thus allowing viral replication to occur unimpeded. The E1B-55kD protein binds to p53 and induces its degradation, whereas the E1B-19kD protein functions similarly to the antiapoptotic factor *Bcl2* (8, 9) thereby preventing the death of the infected cell and allowing viral replication to occur. Other proteins in the early phase of the viral replication cycle are encoded by the *E2* (proteins needed in viral DNA synthesis), *E3* (host immune response modulation and cell lysis), and *E4* (regulation of DNA replication, mRNA transport, and apoptosis) gene clusters. The viral structural proteins and the proteins necessary for assembly of the virion are encoded by genes expressed during the intermediate and late phases of viral replication. Once viral progeny assembly is complete, new viral particles (>1000/cell) are released by cytolysis.

METHODS TO RENDER CYTOLYTIC ADENOVIRUSES TUMOR SPECIFIC

Tumor specificity has been achieved in oncolytic adenoviruses in 3 main ways: (a) by altering viral genes that attenuate replication in normal tissue but not in tumor cells; (b) by placing viral genes that initiate viral replication under the control of promoter sequences that are active in tumor cells; and (c) by the modification of viral coat proteins that function in host cell infection. Included in this review is a table of current oncolytic adenoviruses and their progress toward clinical trial (Table 1).

Attenuating Viral Replication in Normal Cells but Not Tumor cells via Gene Mutation

Replication of the adenovirus genome after infection relies on the ability of the virus to effectively take over the machinery of the host cell. The elucidation of the molecular mechanisms underlying this phenomenon has led to the creation of modified adenoviruses that contain viral gene mutations, which lead to selective viral replication within tumor cells but not in normal cells (Fig. 1).

The first adenovirus gene used in such a strategy is *E1B*. Adenoviral replication activates cellular growth arrest and apo-

ptosis through p53-dependent and -independent mechanisms. The E1B-55kD protein plays a critical role in viral replication by binding to and inactivating the p53 tumor suppressor protein. Mutant adenovirus *dl1520* (also known as ONYX-015 and CI-1042) contains a deletion in the *E1B* gene, preventing the formation of a functional E1B-55kD protein. With this mutation, *dl1520* was expected to replicate only in p53-deficient cells (2) as the loss of E1B activity was expected to prevent viral replication in normal cells due to growth arrest. Expression of the E1B-19kD protein is not affected by the mutation, thus protecting the cell from apoptosis. This was the first oncolytic virus to take advantage of the high percentage of tumors having some mutation that causes the loss of p53 function (10–12). Initial preclinical studies showed that *dl1520* was effective in decreasing tumor size (2, 13, 14).

However, more recent studies show that *dl1520* was able to replicate in cells with a wild-type *TP53* gene (7, 15–20). There are several explanations for these conflicting results. There are other proteins that affect p53 activity in cells, such as p14^{ARF} and mdm2 (2, 21, 22). p14^{ARF} down-regulates mdm2, which is an ubiquitin ligase that stimulates p53 degradation. Cancer cells with a loss in p14^{ARF} gene expression due to gene deletion or with overexpression of mdm2 after gene amplification will create a p53-null phenotype thereby allowing *dl1520* replication in tumors containing a wild-type *TP53* gene. Another explanation involves the adenoviral *E4orf6* gene product, which also binds to p53 and inhibits p53-mediated apoptosis, possibly allowing E1B-55kD-deficient adenoviruses to replicate in cells with wild-type p53 (23).

Another avenue that has been used to make adenoviruses tumor specific is altering the conserved region-2 in *E1A*. In wild-type adenoviruses, the E1A viral protein works to overcome the pRb-mediated inhibition of cell cycle progression. E1A binds with pRb, resulting in the release of Rb-bound E2F transcription factors, which then activate the cell to progress from the G₁ to the S (DNA synthesis) phase of mitosis. E1A-CR2 mutants such as *dl922–947* (24) and $\Delta 24$ (25) have small deletions in this conserved region, which prohibit binding to pRb. Many tumors have a loss of regulation of the G₁-S checkpoint leading to tumor progression. The preclinical studies showed that *dl922–947* preferentially replicated in several different tumor lines and not in normal tissue. An antitumor effect was also demonstrated in xenograft models regardless of the specific defect leading to the dysregulation of the G₁ to S-phase transition. Although this specific modification appeared effective, concerns have been raised if this group of replication competent adenovirus mutants would be able to replicate in normally proliferating tissue, which have physiologically down-regulated proteins that normally inhibit progression from G₁ to the S phase. This concern could restrict the use of these adenoviruses to intratumoral administration to prevent potential toxicity to other organs in the body making it unsuitable for the treatment of metastatic disease. Clinical trials will be needed to evaluate if this potential toxicity will occur.

More recent generations of adenoviruses have combined *E1A* and *E1B* alterations in an effort to additionally improve the selective killing of tumor cells (26). The oncolytic adenovirus AxdAdB-3 carries mutations in both the *E1A* and *E1B-55kD* gene regions limiting its replication to p53- and pRb-deficient

Table 1 Oncolytic adenoviruses*

A. Deletion targeting							
Oncolytic strain	Tumor specific	Modifications	E3 status†	Cells infected	Clinical trial	Reference	
<i>dl1520</i>	Pan	Deleted E1B-55kD	Deletion	p53 null/mutant	Phase I–III	(2, 71, 75, 103–109)	
Δ 24		Deleted E1A CR-2	Deletion	pRb null/mutant	No	(25)	
<i>dl922–947</i>		Deleted E1A CR-2	Deletion	pRb null/mutant	No	(24)	
AxdAdB-3		Deleted E1B-55kD, mutated E1A	Deletion	p53 + pRb null/mutant	No	(26)	
<i>dl1331</i>		Deletion in VAI RNA-coding sequence	Intact	Ras positive	No	(29)	
Ad118	Breast	E1B-55kD, E1B-19kD deletions	Deletion	p53 + pRb null/mutant	No	(110)	
B. Transcriptional targeting							
Oncolytic strain	Tumor specific	Promoter	Gene controlled	E3 status	Cells infected	Clinical trial	Reference
Ad5TRE-E1A	Pan	Tetracycline controlled	E1A, E1B	Deletion	p53 null/mutant	No	(42)
Adv-TERTp-E1A		Telomerase reverse transcriptase (TERT)	E1A	Deletion	TERT+	No	(45)
TEhRT-Ad		TERT	E1A	Intact	TERT+	No	(111)
HYPR-Ad		HIF responsive	E1A	Deletion	HIF+/hypoxic	No	(46)
Ad9xHRE1A		HIF responsive	E1A, E4	Intact	HIF+/hypoxic	No	(47)
Ar6pAE2fE3F		E2F-1	E1A	Deletion	Replicating and pRb null/mutant	No	(112)
ONYX-411		E2F-1	E4, E1A Δ CR2	Deletion	Replicating and pRb null/mutant	No	(36)
AdE2F-1 ^{RC}		E2F-1	E1A	Deletion	Replicating and pRb null/mutant	No	(43)
01/PEME		p53 responsive element	E2F antagonist	Deletion	p53 null/mutant	No	(44)
AdEHT2	Breast	1) Estrogen + hypoxia 2) TERT	1) E1A 2) E4	Intact	Estrogen receptor and TERT +	No	(30)
AdEHE2F		1) Estrogen + hypoxia 2) E2F-1	1) E1A 2) E4	Intact	Estrogen receptor and replicating	No	(30)
Ad.ERE2		pS2 promoter (estrogen responsive)	E1A, E1B	Intact	Estrogen receptor +	No	(38)
Ad.DF3-E1		DF3/MUC1	E1A	Intact	MUC1+	No	(31)
AdhOC-E1	Prostate	Bidirectional osteocalcin promoter	E1A, E1B	Intact	Osteocalcin +	No	(35)
CV787		1) Rat probasin 2) PSA	1) E1A 2) E1B	Intact	PSA+	Phase I	(113)
CV764		1) Human glandular kallikrein 2) PSA	1) E1A 2) E1B	Deletion	PSA+	No	(39)
CN706		PSA	E1A	Deletion	PSA+	Phase I	(33)
AvE1a04i	Liver	AFP	E1A	Intact	AFP+	No	(32)
CV890		AFP	E1A-IRES-Bicistronic cassette	Intact	AFP+	No	(37)
AdTyrwt	Melanoma	Tyrosinase enhancer	E1A	Intact	Tyrosinase+	No	(40)
AdTyr Δ 24		Tyrosinase enhancer	E1A Δ 24 CR-2 2) E4	Intact	Tyrosinase and pRb null/mutant	No	(40)
AdTyr Δ 2 Δ 24		Tyrosinase enhancer	E1A Δ 2(NH ₂ terminus) E1A Δ 24 CR-2	Intact	Tyrosinase and pRb null/mutant	No	(40)
KD1-SPB	Lung	Surfactant B	1) E1A 01, 07 mutants 2) E4	Deletion	Surfactant B+ and pRb null/mutant	No	(41)
vCF11	Colon	Tcf responsive	E1A	Intact	Activated Wnt	No	(114)
AdMKE1	Neuroblastoma	Midkine	E1A	Deletion	Midkine+	No	(115)
AdE3-IAL3B	Ovarian	IAL3B promoter	E1A	Intact	IAL3B+	No	(26)
C. Modified Tropism							
Oncolytic strain	Tumor specific	Modification	E3 status	Cells infected	Clinical trial	Reference	
Ad5/3 Δ 24	Ovarian	1) Incorporation of serotype 3 knob and retaining Ad5 shaft and tail 2) 24 bp deletion in CR2 of E1A	Intact	pRb null/mutant	No	(116)	

Abbreviations: HIF, hypoxia-inducible factor.

* Revised and reprinted with permission from Ref. 1.

† Refer to cited reference for extent of E3 deletions for each virus.




Fig. 1 Attenuating viral replication in normal cells but not tumor cells via gene mutation. For example, by altering a region of the *E1B* gene, the adenovirus can selectively replicate in p53-deficient (*i.e.*, tumor) cells and leave p53-competent cells intact. A single cell infected leads to the production of up to thousands of viral copies. Once the cell lyses, the release of the exponentially increased number of viruses can then spread to adjacent tumor cells, thus propagating tumor cell kill with a single inoculation.

cells. This mutant adenovirus was as effective as an E1B-55kD-deleted adenovirus, AxdAdB (similar to *dl1520*), in preventing growth of gallbladder cancer cells and xenografts. AxdAdB-3 replicated less effectively in normal tissue compared with AxdAdB, proving that combining *E1A* and *E1B* alterations conferred improved selectivity. Although its selectivity and activity were demonstrated, this specificity may limit the use of this virus, because p53 and pRb mutations may not be found in all of the tumor cell types. The potential limitations described for *E1A* and *E1B* altered adenoviruses described above would also apply to AxdAdB-3. Because this mutant carries two deletions, its attenuation may affect its ability to efficiently replicate and spread before achieving its desired cytopathic effect in cancer patients (see below).


Another pathway that has been used to confer tumor selectivity is the interferon pathway. One of the proteins in this pathway is protein kinase R. This kinase, when activated by viral double-stranded RNAs, phosphorylates the α subunit of eIF-2 α , which inhibits viral replication (27, 28). Many viruses including adenoviruses have evolved mechanisms that inhibit protein kinase R (27). One mechanism is the production of viral-associated RNAs, which bind to protein kinase R and block double-stranded RNA binding. The *Ras* oncogene also down-regulates protein kinase R. *dl1331* is a mutant adenovirus created by deleting a region in the viral-associated RNA-coding region and thereby inactivating the viral-associated RNAs (29). Therefore, *dl1331* replication becomes dependent on tumor cells with high expression of *Ras* to inactivate protein kinase R, thus conferring tumor selectivity. Whereas *dl1331* showed antitumor activity, this virus was attenuated compared with wild-type Ad5. Another limitation is that *Ras* mutations occur in only 30% of

tumors, and thereby potentially restricting its use to a subgroup of tumors. One point brought up is whether a *Ras* mutation is always needed to activate this virus, because tumor-specific alterations to other proteins within the *Ras* pathway may lead to constitutive activation of the pathway and subsequent protein kinase R inhibition. More preclinical data will be needed to test if this hypothesis is true.

Use of Overactive Cellular Promoters to Direct Lytic Viral Replication in Tumor Cells

Another method to direct viral specificity to tumor cells is the regulation of viral replication via cellular promoters that are overactive or reactivated in certain tumor cells, sometimes referred to as “tumor-specific” promoters (Fig. 2). Certain tumor types, such as germ cell tumors, prostate cancer, and hepatocellular carcinoma, express proteins that are not normally present in the human body after fetal development. If present, these secreted proteins allow the clinician to have a “tumor” marker that can be followed clinically to look at response to therapy. Other tumors, like breast carcinoma, can have mutations that make these tumors highly sensitive to normally secreted hormones (estrogen). Certain oncolytic adenoviruses (Table 1) have been created to take advantage of the expression of these tumor markers or dependence on normally secreted hormones by placing the *E1A* gene under the control of the promoters derived from the genes of interest (will now be referred to as “tumor-activated” promoters). For example, Ad.ERE2 targets estrogen receptor-positive breast cancer by placing the *E1A* gene under an estrogen responsive element from the *pS2* gene promoter (30). Another breast cancer targeted adenovirus, Ad.DF3-E1, places *E1A* under the control of the *DF3/MUC1* gene promoter

Fig. 2 Use of cellular promoters to direct lytic viral replication to tumor cells. The *E1A* gene (gray arrow) is placed under control of a promoter (dashed rectangle) that is preferentially overactive in a given tumor cell-type. This modification drives viral replication in tumor cells but not normal cells.



(31) to target MUC1+ cancer cells. The oncolytic adenovirus, AvE2a04i (32), was created to target α -fetoprotein (AFP)-expressing hepatocellular carcinoma by placing *E1A* under the control of the *AFP* gene promoter. CV706 targets prostate cancer by placing *E1A* under the control of a promoter derived from the prostate-specific antigen (*PSA*) gene (33). AdhOC-E1 targets prostate tumor cells by using a promoter derived from the *osteocalcin* gene (34, 35), the product of which is also secreted by prostate tumor cells.

Newer generations of oncolytic adenoviruses have been developed to additionally restrict viral replication to tumor cells. Ad.ERE2, AdeHT2, ADEHE2F, ONYX-411, and KD1-SPB place the *E1A* and specific *E4* genes under a “tumor-activated” promoter (30, 35–39). Others have combined transcriptional targeting with viral gene mutations to restrict viral replication. One example is the use of a *tyrosinase* gene promoter to drive expression of an altered *E1A* gene product deficient in binding to the p300 transcriptional activator and the pRb family for the treatment of melanoma (40). In the treatment of bronchoalveolar lung carcinomas, KD1-SPB places transcriptional control of a specific *E4* and an attenuated *E1A* gene under a *surfactant* gene promoter (41). Ad5TRE-E1A is an *E1B*-deleted oncolytic adenovirus, which also has an *E1A* gene controlled by a tetracycline-responsive promoter that allows exogenous control of oncolytic activity by the concomitant administration of doxycycline (42).

One major limitation with the use of these tumor-activated promoters to regulate adenovirus replication is that they are not always active in all tumor types. Even within a tumor, it is unlikely that all of the cells will express a specific tumor marker, because most tumors are heterogeneous; this potentially gives a selective advantage to the remaining nonexpressing cells.

This led to an interest in identifying and designing promoters that are more universally active in all tumor types. As a general feature, tumors usually exhibit some aberrant form of cell growth due to dysregulation of the cell cycle. E2F-1 is an important transcription factor that activates genes that promote the transition from G₁ to S phase of the cell cycle. Tumor cells appear to frequently have constitutively high levels of E2F-1 expression and activity due to a disruption of pathways that control its expression. The AdE2F-1^{RC} virus was created to take advantage of this by placing the *E1A* gene under the regulation of the *E2F-1* gene promoter. This virus was shown to induce cytolysis selectively in tumor cells but not in nonproliferating normal cells (43). However, side effects could occur with such viruses, because viral replication may happen in proliferating normal tissue such as bone marrow, skin, and gastrointestinal mucosa. An alternative strategy was used in Ad 01/PEME (44). This virus was designed with a two-step mechanism to prevent replication in normal tissue. An E2F protein antagonist, composed of the E2F DNA-binding domain and a pRb transrepression domain, was placed under the control of a p53-responsive promoter. This strategy confers selectivity to tumor cells, as a cell generating a functional p53 protein (*i.e.*, normal cells) would express the E2F protein antagonist leading to inhibition of viral and cellular E2F-dependent promoters thus preventing the initiation of viral synthesis. The loss of a functional p53 protein (tumor cells) would allow viral replication to proceed. Newer studies have shown that telomerase activity may also serve as a general marker of neoplastic cells. Its activity in normal cells is restricted to fetal tissue, whereas it is elevated in tumors. Adv-TERTp-E1A was developed by placing the *E1A* gene under the control of a promoter derived from the gene

encoding telomerase reverse transcriptase (*TERT*), the rate-limiting catalytic subunit of telomerase (38, 45).

Hypoxia occurs in virtually all solid tumors as they out-grow their blood supply. Hypoxia augments cellular levels of hypoxia-inducible factor, a transcription factor that regulates target genes through the binding of hypoxia-responsive elements. These include the genes that encode for erythropoietin, the proangiogenic factor vascular endothelial growth factor, and the cascade of glycolytic enzymes necessary for cell survival in low oxygen conditions. Oncolytic adenoviruses were created by placing the regulation of the *E1A* gene under a hypoxia-inducible factor-responsive promoter recently. These viruses showed cytolytic effects only in cells that were hypoxic (46) or that constitutively expressed hypoxia-inducible factor due to a mutation in the von Hippel-Lindau disease (47). These viruses are best used in conjunction with traditional methods such as chemotherapy and radiation, which are more efficient on normoxic tumor cells.

How Attenuated Is too Attenuated?

It is unknown if newer generations of adenoviruses are more effective, because there are few studies comparing different adenoviruses, and these newer viruses must overcome the same obstacles. Some concerns have been raised that as oncolytic viruses become more attenuated, their ability to achieve sufficient cytotoxic effect to reduce tumor growth may not be reached (48, 49). Because many viral proteins (such as E1A, E1B-55kD, and E4) have more than one function, mutations within a viral gene to attenuate the virus may result in needing an increased dose to obtain a measurable antitumor effect in tumor cells.

In addition to its role in the degradation of p53, the E1B-55kD protein has several other important late-phase functions. For example, E1B-55kD is not only involved in blocking p53 apoptosis, but it is also involved in nuclear export of late transcripts that are needed to maximize viral replication. These functional regions of the E1B-55kD protein appear to overlap. By deleting a portion of the gene to create an attenuated virus, the efficiency of viral replication may also be affected. *E1B*-deleted adenoviruses have also been shown to be cold sensitive. It is interesting to note that E1B-attenuated viruses replicate as well as wild-type adenovirus at higher temperatures (39°C). It has been shown that the expression of an inducible heat shock protein (HSP) or exposing the cells to heat shock improves the oncolytic efficacy of a replication competent adenovirus (50). The mechanism by which HSP compensates for E1B-55kD loss is unknown. One way to inactivate p53 binding but not the transport of late viral gene transcripts is to cause a point mutation in the *E1B* gene region that disrupts E1B binding to p53 but does not affect the late-phase function of E1B. R240A (ONYX-051) and H260A (ONYX-053) were created by a single amino acid point mutation (50). Both mutant adenoviruses showed poor activity in binding to p53. Both viruses partially preserved the late functions of wild-type E1B-55kD. Although the antitumor effect was modest compared to *d11520*, the ability to disrupt one viral function while retaining other functions in the same location of the gene show promise to creation of the next generation of oncolytic adenoviruses.

Another method that is used to attenuate adenoviruses is a

deletion in the *E3* region. Proteins encoded by this viral genome region are important in protecting viral replication in the infected cell from cytotoxic T cells and death-inducing cytokines (51). Loss of these proteins could affect how quickly the body will respond to a viral infection thereby preventing an oncolytic adenovirus from achieving its maximal effect (52). Not all of the oncolytic adenoviruses have a deletion in the *E3* region (Table 1), and additional clinical trials will be needed to compare antitumor efficacy among adenoviruses that have a full *E3* region or a partially deleted *E3* region, because an immune response may only be demonstrated in humans.

Because many viral gene functions are derived from a small set of genes, attenuation of viruses should be approached cautiously so that maximum viral replication efficiency can be maintained despite limiting its selectivity. As our understanding of the roles of each gene is elucidated, newer generations of oncolytic adenoviruses will hopefully maximize replication efficiency while maintaining their ability to selectively target tumor cells.


Targeting Viral Infection to Tumor Cells through Alterations in Viral-Host Cell Interactions

The above approaches have relied on the ability of the adenovirus to infect a number of different tissue types and then restrict viral replication once it has entered the cell. There are two main drawbacks to such methods. First, not all of the tumor cells will express the particular receptor that will allow oncolytic adenoviruses to infect the cell (53–55). Another problem is that a nontargeted tissue type (typically the liver) may strongly express the particular receptor for viral binding and serve as a physiologic “sink” by binding a majority of the desired dose of the virus. To overcome these limitations, certain laboratories have been able to alter the structural viral envelope proteins to retarget the virus to tumor cell surfaces and direct the virus away from its normal receptor (Fig. 3).

Two different interactions take place that allow infection of a cell by an adenovirus (6). The attachment of adenoviruses type 2 and 5 to a cell is initiated by interaction of the knob domain of the viral fiber protein with cell surface proteins such as the coxsackie-adenovirus receptor (53, 56). After attachment, the Arg-Gly-Asp (RGD) peptide sequence within the viral penton protein interacts with $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins, which then leads to the internalization of the virus by receptor-mediated endocytosis. Not all of the adenovirus serotypes use coxsackie-adenovirus receptor, and the cellular receptors for these viruses are currently unknown. Tumor cells express varying amounts of viral-binding receptors (57–64), and during oncogenesis, expression of these receptors can be lost (65). Furthermore, oncolytic virotherapy will create selection pressure for survival of tumor cells that do not express viral-binding receptors.

Δ to Ad Δ 24 was created by incorporating an additional RGD motif (RGD-4C) into the fiber knob (66). This allowed the virus to attach directly to the $\alpha_v\beta_3$ and $\alpha_v\beta_5$ integrins on the cell surface. This modification allowed improved infection of glioma cells, because <50% of glial cells express coxsackie-adenovirus receptor, whereas >50% express integrins. This virus improved the survival of mice-carrying glioma xenografts. Adv-E1BdB-F/K20 incorporated lysine residues into the fiber protein to allow binding to heparin sulfate receptors, which are

Fig. 3 Targeting viral infection to tumor cells through alterations in viral-host cell interactions. Adenovirus type 2 and 5 used for most current viral vectors rely on coxsackie-adenovirus receptor (*CAR*) to attach to the cell. Once attached, the adenoviral penton protein interacts with cellular integrins via an RGD motif resulting in endocytosis of the adenovirus. Because not all of the cells will have *CARs*, one modification would be to incorporate the RGD motif into the knob protein that normally binds to the *CAR* (see extension on knob circle in virus on right). By adding this motif to the knob protein, the oncolytic adenovirus can infect a broader range of tumor cells, because $\alpha_v\beta_{3/5}$ integrins are expressed on a majority of cells. This modification can be in addition to the modifications shown in Figs. 1 or 2.



more widely expressed. Adv-E1BdB-F/K20 also carries a defective *E1B* gene (67, 68).

To improve Ad5 infection of renal carcinoma cells (low levels of Ad5-binding coxsackie-adenovirus receptor expression and high expressions of Ad3-binding receptors), the fiber protein was switched to contain an Ad3 knob instead of an Ad5 knob. Modification of a virus tropism by borrowing cell binding properties of other serotypes or viral species is known as pseudotyping. This fusion fiber protein was able to augment infectivity of the pseudotyped adenovirus in renal cell carcinoma cells *in vitro* and *in vivo* (63).

Another modification is the development of a polymer that coats the adenovirus and allows incorporation of desired targeting ligands. This polymer not only broadens the types of tissue the adenovirus can infect but also helps it resist antibody neutralization (69). This system is useful to augment initial infection by replicative adenoviruses, but viral progeny will not have this polymer coat. Further studies are also needed to evaluate whether altering the viral coat will prevent the liver from absorbing most of the injected dose of adenovirus.

These studies provide evidence that the tropism of replication competent adenoviruses can be altered leading to an enhancement of antitumor activity. However, the improved infective capabilities of these adenoviruses may cause infection of non-neoplastic tissue. Unfortunately, to date there have been no clinical trials to show how these variables will affect the efficacy of an oncolytic adenovirus.

Efficacy, Safety, and Routes of Administration

To date, *d11520*, CV706, and CV890 have been evaluated in clinical trials. *d11520* has undergone extensive testing and

been found to be relatively safe in multiple modes of delivery, including intratumorally, intraperitoneally, intra-arterially, or intravenously (70). Flu-like symptoms were the most common reported toxicity. The incidence of flu-like symptoms appears to be associated with the mode of delivery being highest among patients receiving intra-arterial or intravenous injections. Patients receiving intratumoral injections have also developed flu-like symptoms, most probably due to a partial injection of virus into a blood vessel within the tumor. The flu-like symptoms are thought to be due to an increase in inflammatory cytokines such as tumor necrosis factor α (TNF- α), interleukins (IL-1 and IL-6), and interferon γ (71, 72). Other reported side effects of adenovirus administration are transient elevation of liver transaminases and reversible hyperbilirubinemia (71, 72). There has been no clinical evidence of progressive hepatotoxicity from the administration of oncolytic adenoviruses. This was an initial concern, because 1 patient has died after receiving a hepatic intra-arterial infusion of 4×10^{13} particles of a replication-deficient adenovirus for the treatment of ornithine transcarbamylase deficiency (73).

Therapeutic response to *d11520* treatment has been variable depending on the mode of delivery with intratumoral injection of virus resulting in the best antitumor response. Administration of *d11520* via intratumoral injections was performed on patients with advanced head and neck squamous cell carcinoma (74, 75). Patients either received single daily dose ($n = 30$) or fractionated twice daily dosing of *d11520* ($n = 10$). Of patients receiving a single daily dose of *d11520*, 14% achieved a partial or complete response *versus* 10% of the patients receiving fractionated daily doses, which was not significant in this small study. This response correlated with *TP53* gene status of the tumor with

58% (7 of 12) of p53 mutant tumors showing regression compared with no response among the p53 wild-type tumors. Furthermore, necrosis was confined to treated tumor tissue with no damage to adjacent normal tissue. Viral spread was documented in tumor tissue 5–14 days after treatment, even in the presence of high neutralizing antibody titers.

Other modes of viral delivery have been less effective compared with intratumoral injections. A clinical trial was performed that examined intra-arterial administration of *d11520* (72) in patients with metastatic gastric carcinoma to the liver. The response to viral therapy was modest with no complete responses and 7 of 28 patients having some measurable decrease in size of the tumor. However, 3 patients who had refractory disease to chemotherapy (5-fluorouracil) had a minor response with administration of *d11520*. These patients also had delayed viremia. The decrease in tumor size along with delayed viremia occurred despite having high neutralizing antibody titers. Overall, the addition of *d11520* along with 5-fluorouracil proved to be safe, with 2 patients developing reversible direct hyperbilirubinemia (grade 3/4). During this study, 1 patient suffered from a severe inflammatory reaction after hepatic intra-arterial administration of *d11520*. Unique to this patient was the absence of IL-10 and a 20-fold increase in IL-6 (72), and this patient recovered from this reaction. The results of intra-arterial administration of oncolytic adenoviruses have also proven safe in the treatment of cancer.

Another study looked at the feasibility of intravenous administration of oncolytic adenoviruses. A Phase I trial was performed in patients with metastatic carcinoma to the lung (71). *d11520* was infused intravenously in escalating doses of 2×10^{10} to 2×10^{13} particles. Because there were no dose-limiting toxicities, the intravenous administration of adenoviruses proved feasible. Although there were no documented responses with *d11520* alone, tumor stabilization (6.5+ months) was noted in patients who had failed chemotherapy alone supporting that the combination of oncolytic virotherapy and chemotherapy could be synergistic (see below).

Although the routes of administration of oncolytic adenoviruses have had mixed responses, there have been several positive results from these trials. The treatment is tolerated with acceptable toxicities that have been reversible. Whereas intratumoral treatment alone has appeared to only modestly reduce tumor size, the potential synergy with chemotherapy is very promising. Because not all sites are amenable to intratumoral therapy, intravenous administration would be the ideal solution, because it can reach nonoperable sites and multiple metastatic sites. There is evidence to support that the key to efficient tumor control is dependent on the quantity of virus that reaches the tumor (76). Two limiting steps would be neutralizing antibodies and sequestration of viral particles in organs, such as the liver, not affected by tumor. The response of intra-arterial and intravenous injections appears not to be affected by neutralizing antibodies. What may be affected is the number of viral particles reaching a given tumor. Neutralizing antibodies could potentiate increased clearance by the liver. It is unclear from the above studies whether the toxicities experienced by the patients with i.v. administration were noted with each injection of *d11520*. Ongoing clinical studies with Newcastle disease virus show that a process called “desensitization” occurs where toxicities be-

come less severe and less frequent with subsequent treatments thereby allowing higher doses of virus to be injected. One possible reason is that desensitization is related to immune tolerance such as giving allergy shots to a patient. Although there may be release of neutralizing antibodies, the inflammatory response may be modified so that patients are less symptomatic with subsequent doses of the virus. Work using 01/PEME adenovirus showed that intravenous injection was ~1000-fold less efficient in the prevention of tumor growth in mouse xenograft models compared with intratumoral injections and that this limitation could be overcome by giving a higher initial dose of adenovirus (76). Being able to give higher doses in longer infusions has improved tumor response with Newcastle disease virus (77). Newer clinical studies are needed to determine whether these recent insights are also applicable to adenoviruses. Other potential studies could combine the polymer coating system (above) with oncolytic adenoviruses that would target the desired tissue, possibly bypassing the liver and neutralizing antibodies and thus improve the initial infection rate of tumor cells. Additional investigation is also needed in attenuating the virus for normal tissue but not affecting the efficiency of viral replication.

THE ROLE OF ONCOLYTIC ADENOVIRUSES IN COMBINATION CANCER THERAPY

Current limitations of chemotherapy and radiation therapy are their inability to effectively treat metastatic disease. As with other modalities of treatment, oncolytic virotherapy, by itself, has not been effective in complete tumor eradication in both preclinical animal models and clinical studies. It appears that the best chance for complete tumor eradication lies with combining its mechanism of action with current treatment strategies of chemo- and radiation therapies and the emerging field of clinical gene therapy. The theory, based on combination chemotherapy, is that attacking tumor cells through different mechanisms of action will prevent tumor cells from having time to develop resistance to treatment. There have been several clinical trials looking at the benefit of adding oncolytic adenoviruses to radiation therapy, chemotherapy, and gene therapy.

Oncolytic Adenoviruses and Chemotherapy

Despite using multiagent chemotherapy at maximal tolerated doses along with surgical resection, tumor recurrences are still common. Oncolytic virotherapy has shown promising results in combination with chemotherapy in preclinical models (Table 2). The addition of oncolytic adenoviruses appears to augment tumor kill when added to treatment with chemotherapy (12, 34, 75–78). The order in which chemotherapy and oncolytic adenoviruses are administered may also affect the efficacy of tumor cell death (76, 78). One interesting result suggests that chemotherapy could reduce the amount of viral particles needed to help eradicate the tumor (75).

The addition of oncolytic adenoviruses to chemotherapy has already entered Phase II trials with promising results. One such trial evaluated the use of intratumoral *d11520* injection in combination with cisplatin and 5-fluorouracil therapy in patients with recurrent squamous cell carcinoma of the head and neck. Sixty-three percent of patients (19 of 30) had a measurable

Table 2 Oncolytic adenoviruses in combination cancer therapy*

Oncolytic strain		Tumor targeted	Effect	Studies	Reference	
Ad with Chemotherapy <i>dl1520</i> (ONYX-015)	Chemotherapy agent					
	5-FU + leucovorin	Metastatic gastric carcinoma (liver)	Modest shrinkage	Phase II	(72)	
	Cisplatin + 5-FU	Squamous cell carcinoma (recurrent)	Improved anti-tumor response	Phase II	(78, 79)	
	Doxorubicin or paclitaxel	Thyroid	Synergistic	<i>in vitro</i>	(117)	
	Cisplatin + paclitaxel	Lung (NSCLC)	Synergistic	<i>in vitro</i>	(118)	
	5-FU + cisplatin	1) Squamous cell carcinoma (head/neck) 2) Ovarian	1) Enhanced 2) Enhanced	<i>in vivo</i>	(119)	
	Cisplatin	Squamous cell carcinoma (head/neck)	Enhanced	<i>in vivo</i>	(14)	
5-FU	1) Squamous cell carcinoma (head/neck) 2) colon	Enhanced	<i>in vivo</i>	(14)		
CV787	Paclitaxel or docetaxel	Prostate	Synergistic	<i>in vitro/in vivo</i>	(81)	
CV890	Doxorubicin	Liver	Synergistic	<i>in vitro/in vivo</i>	(37)	
Ad with Radiation Therapy	Radiation dose					
	Ad FGR (Ad5-CD/TKrep)	50–74 Gy	Prostate	Enhanced	Phase I	(85)
		8–10 Gy	Cervical	Enhanced	<i>in vivo</i>	(95)
		0–6 Gy	Glioma	Enhanced	<i>in vitro</i>	(94)
		0–6 Gy	Prostate	Enhanced	<i>in vitro</i>	(94)
	<i>dl1520</i> (ONYX-015)	5 Gy (total body irradiation)	Glioma	Enhanced	<i>in vivo</i>	(82)
		2 or 20 Gy	Colon	Enhanced	<i>in vivo</i>	(13)
		0–6 Gy	Thyroid	Enhanced	<i>in vitro/in vivo</i>	(120)
	Ad5Δ24RGD	3 Gy <i>in vitro</i>	Glioma	Enhanced	<i>in vitro/in vivo</i>	(86)
	CV706	5 Gy <i>in vivo</i>				
	10 Gy	Prostate	Synergistic	<i>in vitro/in vivo</i>	(87)	
Ad with Gene Therapy	Gene					
	Ad Ig.Ad5E1 ⁺ E3TK	Thymidine kinase	Glioma	Enhanced	<i>in vivo</i>	(89)
	Ad.TK ^{RC}	Thymidine kinase	Colon, cervical, melanoma	Enhanced	<i>in vivo</i>	(84)
			Lung, ovarian	Mixed or no effect	<i>in vivo</i>	(90)
	Ad.wt.TK	Thymidine kinase	Lung	No effect	<i>in vivo</i>	(92)
	Ad FGR (Ad5-Cd/TKrep)	Cytosine deaminase	Prostate, glioma	Enhanced	Phase I, <i>in vitro/in vivo</i>	(85)
	Ad.DF3-E1/CMV-TNF	Thymidine kinase				
	Ad5/IFN	TNF-α	Breast	Enhanced	<i>in vivo</i>	(92)
	Ad-HE	Interferon consensus	Breast	Enhanced	<i>in vivo</i>	(98)
	<i>dl1520</i> -CE	HSP70	Pan	Enhanced	<i>in vitro/in vivo</i>	(100)
	AdDelta24-p53	Carboxylesterase	Pan	Enhanced	<i>in vivo</i>	(97)
		P53	Pan	Enhanced	<i>in vitro</i>	(102)

* Revised and reprinted with permission from Ref. 1.

decrease in tumor size (>50%). Eight of 30 (27%) had complete responses (no measurable disease), whereas 11 of 30 (36%) had partial regression [decrease of 50–100% in tumor area; (78, 79)]. This is an improvement when compared with historical data of a 14% measurable response (>50%) in patients treated with *dl1520* alone and 30–40% response for chemotherapy alone (80). The combination therapy was well tolerated and did not lead to an apparent increase in toxicity. Most importantly, it was also shown that viral replication was not inhibited by this chemotherapy regimen (78). In addition, the response did not correlate with initial tumor size, presence of pretreatment neutralizing antibodies, *TP53* gene status, or prior treatments. Another Phase II trial looked at the combination of *dl1520* with leucovorin and 5-fluorouracil in patients with gastrointestinal carcinoma metastatic to the liver. Although results were modest (11% with complete response and 15% with partial responses),

overall safety was established. Despite having an initial increase in tumor size on imaging, 43% of the patients had significant tumor shrinkage months after the initiation of viral therapy and a decrease in serum tumor marker levels. This suggests that inflammation associated with viral infection may mask the cytolytic effect of viral replication and tumor shrinkage (68–73).

In summary, these studies on combination oncolytic adenovirotherapy and chemotherapy have shown greater antitumor efficacy without an increase in toxicity. Although the mechanism of the enhanced effects of combining oncolytic virotherapy and chemotherapy is unknown, several hypotheses exist. One is that the virus may increase the cell killing effects of chemotherapy through its ability to induce p53-dependent and -independent apoptotic pathways. In support of this, combination treatment with CV787 and docetaxel shows increased p53

expression in LNCaP cells (81). Because most chemotherapeutic agents are immunosuppressive, this may allow a higher dose of viral particles to reach the tumor when injected systemically (intravenously or intra-arterially) and maintain viral spread intratumorally due to a decrease in the production of neutralizing antibodies. Additional clinical trials will be needed to study the timing of when to administer oncolytic adenoviruses within a chemotherapeutic regimen to achieve the best antitumor response.

Oncolytic Adenoviruses and Radiation Therapy

Oncolytic virotherapy kills tumor cells by a mechanism different from radiation therapy. Radiation therapy-induced tumor cell death is dependent on directly damaging DNA or indirectly through the formation of oxygen radicals that disrupt cellular pathways. This dual mechanism is different from how oncolytic viruses destroy tumor cells. This has led to several preclinical trials looking at the role of combining these two modalities (Table 2). Intra-arterial injections of *dl1520* in conjunction with total body irradiation (5 Gy) were evaluated in subcutaneous human malignant glioma xenograft models that were either p53 mutant or p53 wild-type (82). Significant tumor growth delays were noted in the p53 mutant tumors receiving combination therapy *versus* monotherapies (30 days *versus* 10–15 days). There was also an increase in the number of partial and complete responses in the combined treatment group compared with animals treated with radiation or *dl1520* alone. Enhanced antitumor action was also shown with combination *dl1520* and radiation therapy in xenograft models of human colon cancer in the same study. Both tumor-free survival and average tumor growth delay were higher in the combined treatment group compared with rodents receiving radiation or *dl1520* monotherapies (13). Enhanced antitumor efficacy was also shown in combination studies involving Ad5- Δ 24RGD, CV706, and AdFGR (83–85). Of note, 10^6 plaque-forming units of Ad5- Δ 24RGD in conjunction with radiation therapy achieved similar antitumor effects as 10^7 plaque-forming units of Ad5- Δ 24RGD alone, suggesting that reduced viral treatment doses can be used in combination therapy and still attain a comparable therapeutic effect than oncolytic adenovirus alone.

In summary, these preclinical studies in combining oncolytic adenoviruses with radiation therapy provided several important findings. Radiation did not appear to impair viral replication (13, 82, 86, 87). However, this will need to be additionally studied when fractionated doses of radiation are given rather than a single dose. There also appears to be no additive toxicities noted in the virus plus radiation-treated groups compared with the monotherapy groups (13, 87). Furthermore, these preclinical studies point to enhanced antitumor effects when compared with monotherapy. Another interesting finding is, like in combination with chemotherapy, the order in which oncolytic adenoviral therapy and radiation therapy are administered may be important. Two of the studies showed (12, 83) that radiation could potentiate the cytolytic effect of the adenoviruses. More studies will be needed to evaluate whether this finding is more universal or is restricted to particular experimental conditions, cell lines, or oncolytic adenoviruses. These preclinical studies support moving forward the incorpor-

ation of oncolytic adenoviruses into radiation treatment into clinical trials.

Oncolytic Adenoviruses and Gene Therapy

Many oncolytic adenoviruses have the cloning capacity for a small transgene. Addition of an adjuvant therapy transgene could augment killing the infected tumor cells as well as non-infected tumor cells nearby, a property referred to as the bystander effect (Table 2). One group of therapeutic genes that have received much attention is the prodrug-activating genes, also known as suicide genes. In this system, tumor cells are transduced with a gene that codes for an enzyme that converts a noncytotoxic prodrug into a toxic agent (83). The most studied prodrug-activating gene system involves the prodrug gancyclovir and the HSV thymidine kinase (HSV-*tk*) gene. HSV-*tk* monophosphorylates gancyclovir, which is then converted into gancyclovir triphosphate by other cellular kinases. This toxic metabolite inhibits both viral and cellular DNA synthesis and can spread to nontransduced tumor cells via gap junctions, thereby enhancing the killing effect beyond the infected cell (bystander effect). The antitumor effect of incorporating this system into adenoviruses (IG.Ad5E1⁺E3TK and Ad.TK^{RC}) has been mixed, with some studies showing increased antitumor effect when compared with virus alone (84, 88, 89), whereas others have not (90–92). The mixed findings could be due to gancyclovir inhibiting viral replication. Another reason for the variable effect could be that the number of gap junctions vary among different tumor subtypes (93) leading to a weaker bystander effect. The intracellular accumulation of activated gancyclovir due to lack of spread through the gap junctions would then lead to inhibition of viral replication dominating over viral-mediated oncolysis.

Another replication competent adenovirus, AdFGR (also known as Ad5-CD/TK^{rep}), uses a double-suicide transgene approach. This virus is E1B-55kD null and contains a cytosine deaminase-*tk* fusion gene (94). Cytosine deaminase converts 5-fluorocytosine into 5-fluorouracil, which has antitumor activity. The antitumor effect of this virus is enhanced when used in combination with gancyclovir (intravenously) and 5-fluorocytosine (orally) *in vitro* and *in vivo* compared with virus alone or in combination with a single prodrug (94, 95). Furthermore, the addition of radiation therapy to gancyclovir, 5-fluorocytosine, and virotherapy led to greater tumor growth delay and an 80% (4 of 5) complete response that was superior to other treatment strategies (95). The double prodrug system of AdFGR has entered Phase I clinical trials in patients being treated for recurrent prostate cancer. The adenovirus was administered intraprostatically followed by administration of 5-fluorocytosine and gancyclovir 2 days later (96). There was no dose-limiting step, because it was found safe at all of the levels, and no maximum tolerated dose was reached. Therapeutic response was documented with a reduction in prostate-specific antigen and histologic evidence. AdFGR has also been studied in a Phase I trial in conjunction with radiation therapy in newly diagnosed intermediate- and high-risk prostate cancer patients (85). Transgene expression was observed 3 weeks after injection. The mean prostate-specific antigen half-life was significantly lower in patients receiving >1 week of prodrug therapy compared with radiation therapy alone (0.6 *versus* 2.4 months). Although prom-

ising, additional investigation is needed as to how both 5-fluorouracil and activated gancyclovir will affect oncolytic viral replication, because timing and dosing of each agent is still being investigated. Another prodrug converting enzyme that looks promising for clinical trials is carboxylesterase. This enzyme converts the chemotherapeutic agent irinotecan into a more potent chemotherapeutic agent, SN-38 (97). A recent study looked at *dll1520* expressing the transgene for carboxylesterase. This prodrug converting enzyme strategy has antitumor effects in both *in vitro* and *in vivo* studies.

The incorporation of cytokine genes has also been investigated. Ad.DF3E1 is modified to constitutively express TNF- α using the cytomegalovirus promoter (AD.DF3E1/cytomegalovirus-TNF; Ref. 31). TNF- α is an inflammatory cytokine that has antitumor effects. Viral replication was not affected by expression of TNF- α . Furthermore, treatment with Ad.DF3-E1/cytomegalovirus-TNF had a prolonged tumor regression, whereas Ad-DF3E1 (lacks TNF- α transgene) or adenovirus cytomegalovirus-TNF (replication deficient) led only to suppression of tumor growth. Besides TNF, the human interferon consensus gene has also been incorporated into an oncolytic adenovirus (Ad5/interferon). This also appears to potentiate the oncolytic effect of the adenovirus (98). However, the antiviral activity of interferon was not examined in this study.

Another area of cancer research is the use of tumor vaccines. Although not capable of stimulating a robust immune response, tumor cells do have antigenic peptides that are immunogenic and could potentially induce tumor-specific immunity. One method to overcome this lack of immunogenicity is the use of HSPs. HSPs have a variety of functions. One main function is to act as chaperone proteins that aid in the folding and translocation of cellular peptides (99). The HSP70 family also helps in the presentation and processing of antigen to CD4⁺ T cells by antigen-presenting cells. It is thought that because HSPs act as chaperone proteins, overexpressing HSPs within tumor cells may enhance the immunogenicity of normally weak tumor antigens by presenting the HSP-bound tumor peptides to antigen-presenting cells via the major histocompatibility complex class I pathway. Initial vaccines were not practical, because the vaccine needed to be prepared *ex vivo* with processed tumor cells. As an alternative approach, the gene for HSP70 was incorporated into Ad-E, a E1B-55kD deficient virus, to make Ad-HE (100). This virus effectively impeded the growth of the viral-infected tumor as well as in the contralateral untreated tumor. Ad-HE was also able to prevent tumor growth after rechallenging the rodents with a second injection of tumor cells thereby demonstrating a vaccination effect.

Many malignant neoplasms have lost the function of p53. Although many oncolytic adenoviruses use p53-dependent pathways to cause cell death, several studies have shown that replicating adenoviruses kill cells more rapidly when expressing p53 (19, 101). A conditionally replicative adenovirus, Ad Δ 24-53, was created to express p53 in p53-deficient tumor cells during viral replication (102). The expression of p53 enhanced the killing potential of these oncolytic adenoviruses. The ability to express p53 in otherwise deficient cells will need to be studied in the broader context of multimodal therapy, because it could also improve the killing efficiency of chemotherapy and radiation therapy.

These studies have demonstrated various ways in augment-

ing the antitumor effect of oncolytic adenoviruses via the incorporation of transgenes that encode proteins with antitumor activity. Larger studies will be needed to see if these initial results are applicable to a broad range of tumors. The preclinical antitumor activity of cancer therapy Ads carrying immune modulator transgenes are currently performed in immunocompromised rodents using xenografted human tumor cells. Therefore the full potential of these Ads will not be evident without clinical studies.

CONCLUSIONS AND FUTURE DIRECTIONS

With the overall safety oncolytic adenoviruses have shown in preclinical and clinical trials and studies suggesting that combining these viruses with conventional therapies has an enhanced antitumor effect, oncolytic virotherapy has proven to be a viable treatment modality to specifically kill tumor cells. Significant advances have been made in targeting viral infection and replication to tumor cells. These have relied on our improved understanding of the mechanisms of cancer formation and viral replication. Continuous progress in elucidating these mechanisms will be additionally exploited by oncolytic virotherapy. Preclinical trials have highlighted some strengths and limitations of oncolytic adenovirus treatment. More clinical trials are needed to bridge the gap in preclinical testing and antitumor response in humans, because there is no good animal model to simulate the response of a human to an oncolytic adenovirus infection. Newer imaging techniques like positron emission test imaging may help to better understand the dynamics of viral replication in tumors and within the human body without relying on pathological specimens. Finding reporter probes that can be detected by positron emission test scanners will aid in monitoring the spread of oncolytic adenoviruses *in vivo*. Additional investigation is also needed to establish where in the scheme of treatment oncolytic viruses will have the most benefit. Additional work is needed to improve our ability to deliver adenoviruses intravenously to improve its ability to treat metastatic disease without being sequestered in the liver or subclinical disease that is not detected by current imaging techniques. If clinical studies show significant improvements in survival, the doses of chemotherapy and radiation could be reduced to spare the potential late effects (secondary malignancies, organ toxicities, and neuro-cognitive deficits), which is particularly important in the pediatric oncology setting as more children survive. Other studies are needed to combine different oncolytic viruses to harness the benefits of different antitumor mechanisms and determine what effects they will have on the tumor. The field of oncolytic virotherapy has now matured beyond the initial euphoria. Valuable lessons have been learned that will re-ignite enthusiasm in the further development and clinical testing of second and third generations of these agents. As with other anticancer agents, it is clear that the inclusion of oncolytic adenoviruses into multimodal cancer treatment with chemotherapy, radiation therapy, and gene therapy will be most effective in improving the overall survival of cancer patients.

ACKNOWLEDGMENTS

We would like to acknowledge the AFLAC Corporation and CURE Childhood Cancer organization in their efforts to support the physicians

of the AFLAC Cancer and Blood Disorder Center to further the goal of curing childhood cancer, as well as providing support to children diagnosed with cancer and their families in the state of Georgia.

REFERENCES

- Post DE, Khuri FR, Simons JW, Van Meir EG. Replicative oncolytic adenoviruses in multimodal cancer regimens. *Hum Gene Ther* 2003;14:933–46.
- Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. *Science (Wash DC)* 1996;274:373–6.
- Ring CJ. Cytolytic viruses as potential anti-cancer agents. *J Gen Virol* 2002;83:491–502.
- Chiocca EA. Oncolytic viruses. *Nat Rev Cancer* 2002; 2:938–50.
- Hawkins LK, Lemoine NR, Kirn D. Oncolytic biotherapy: a novel therapeutic platform. *Lancet Oncol* 2002;3:17–26.
- Fields BN, Knipe DM, Howley PM. *Fields virology*. Philadelphia: Lippincott-Raven, 1996.
- Gallimore PH, Turnell AS. Adenovirus E1A: remodelling the host cell, a life or death experience. *Oncogene* 2001;20:7824–35.
- White E, Cipriani R, Sabbatini P, Denton A. Adenovirus E1B 19-kilodalton protein overcomes the cytotoxicity of E1A proteins. *J Virol* 1991;65:2968–78.
- White E, Sabbatini P, Debbas M, Wold WS, Kusher DI, Gooding LR. The 19-kilodalton adenovirus E1B transforming protein inhibits programmed cell death and prevents cytolysis by tumor necrosis factor α . *Mol Cell Biol* 1992;12:2570–80.
- Fulci G, Van Meir EG. p53 and the CNS: tumors and developmental abnormalities. *Mol Neurobiol* 1999;19:61–77.
- White E. Tumour biology: p53, guardian of Rb. *Nature (Lond)* 1994;371:21–2.
- Fulci G, Ishii N, Van Meir EG. p53 and brain tumors: from gene mutations to gene therapy. *Brain Pathol* 1998;8:599–613.
- Rogulski KR, Freytag SO, Zhang K, et al. In vivo antitumor activity of ONYX-015 is influenced by p53 status and is augmented by radiotherapy. *Cancer Res* 2000;60:1193–6.
- Heise C, Sampson-Johannes A, Williams A, McCormick F, Von Hoff DD, Kirn DH. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. *Nat Med* 1997;3: 639–45.
- Petit T, Davidson KK, Cerna C, et al. Efficient induction of apoptosis by ONYX-015 adenovirus in human colon cancer cell lines regardless of p53 status. *Anticancer Drugs* 2002;13:47–50.
- Georger B, Grill J, Opolon P, et al. Oncolytic activity of the E1B-55 kDa-deleted adenovirus ONYX-015 is independent of cellular p53 status in human malignant glioma xenografts. *Cancer Res* 2002;62: 764–72.
- Harada JN, Berk AJ. p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication. *J Virol* 1999;73: 5333–44.
- Rothmann T, Hengstermann A, Whitaker NJ, Scheffner M, zur Hausen H. Replication of ONYX-015, a potential anticancer adenovirus, is independent of p53 status in tumor cells *J Virol* 1998;72:9470–8.
- Hall AR, Dix BR, O'Carroll SJ, Braithwaite AW. p53-dependent cell death/apoptosis is required for a productive adenovirus infection. *Nat Med* 1998;4:1068–72.
- Goodrum FD, Ornelles DA. p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. *J Virol* 1998; 72:9479–90.
- Yang CT, You L, Uematsu K, Yeh CC, McCormick F, Jablons DM. p14^{ARF} modulates the cytolytic effect of ONYX-015 in mesothelioma cells with wild-type p53. *Cancer Res* 2001;61:5959–63.
- Ries SJ, Brandts CH, Chung AS, et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). *Nat Med* 2000;6:1128–33.
- Aoyagi M, Higashino F, Yasuda M, et al. Nuclear export of adenovirus E4orf6 protein is necessary for its ability to antagonize apoptotic activity of BH3-only proteins. *Oncogene* 2003;22:6919–27.
- Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. *Nat Med* 2000;6:1134–9.
- Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. *Oncogene* 2000;19:2–12.
- Fukuda K, Abei M, Ugai H, et al. E1A, E1B double-restricted adenovirus for oncolytic gene therapy of gallbladder cancer. *Cancer Res* 2003;63:4434–40.
- Katze MG, He Y, Gale M Jr. Viruses and interferon: a fight for supremacy. *Nat Rev Immunol* 2002;2:675–87.
- Williams BR. PKR; a sentinel kinase for cellular stress. *Oncogene* 1999;18:6112–20.
- Cascallo M, Capella G, Mazo A, Alemany R. Ras-dependent oncolysis with an adenovirus VAI mutant. *Cancer Res* 2003;63:5544–50.
- Hernandez-Alcoceba R, Pihajla M, Qian D, Clarke MF. New oncolytic adenoviruses with hypoxia- and estrogen receptor-regulated replication. *Hum Gene Ther* 2002;13:1737–50.
- Kurihara T, Brough DE, Kovessi I, Kufe DW. Selectivity of a replication-competent adenovirus for human breast carcinoma cells expressing the MUC1 antigen. *J Clin Invest* 2000;106:763–71.
- Hallenbeck PL, Chang YN, Hay C, et al. A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma. *Hum Gene Ther* 1999;10:1721–33.
- Rodriguez R, Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR. Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. *Cancer Res* 1997;57:2559–63.
- Matsubara S, Wada Y, Gardner TA, et al. A conditional replication-competent adenoviral vector, Ad-OC-E1a, to cotarget prostate cancer and bone stroma in an experimental model of androgen-independent prostate cancer bone metastasis. *Cancer Res* 2001;61:6012–9.
- Hsieh CL, Yang L, Miao L, et al. A novel targeting modality to enhance adenoviral replication by vitamin D(3) in androgen-independent human prostate cancer cells and tumors. *Cancer Res* 2002;62: 3084–92.
- Johnson L, Shen A, Boyle L, et al. Selectively replicating adenoviruses targeting deregulated E2F activity are potent, systemic antitumor agents. *Cancer Cell* 2002;1:325–37.
- Li Y, Yu DC, Chen Y, Amin P, Zhang H, Nguyen N, Henderson DR. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin. *Cancer Res* 2001;61:6428–36.
- Hernandez-Alcoceba R, Pihajla M, Wicha MS, Clarke MF. A novel, conditionally replicative adenovirus for the treatment of breast cancer that allows controlled replication of E1a-deleted adenoviral vectors. *Hum Gene Ther* 2000;11:2009–24.
- Yu DC, Sakamoto GT, Henderson DR. Identification of the transcriptional regulatory sequences of human kallikrein 2 and their use in the construction of calydon virus 764, an attenuated replication competent adenovirus for prostate cancer therapy. *Cancer Res* 1999;59:1498–504.
- Nettelbeck DM, Rivera AA, Balague C, Alemany R, Curiel DT. Novel oncolytic adenoviruses targeted to melanoma: specific viral replication and cytolysis by expression of E1A mutants from the tyrosinase enhancer/promoter. *Cancer Res* 2002;62:4663–70.
- Doronin K, Kuppuswamy M, Toth K, et al. Tissue-specific, tumor-selective, replication-competent adenovirus vector for cancer gene therapy. *J Virol* 2001;75:3314–24.
- Fechner H, Wang X, Srour M, et al. A novel tetracycline-controlled transactivator-transrepressor system enables external control of oncolytic adenovirus replication. *Gene Ther* 2003;10:1680–90.
- Tsukuda K, Wiewrodt R, Molnar-Kimber K, Jovanovic VP, Amin KM. An E2F-responsive replication-selective adenovirus targeted to the

- defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell. *Cancer Res* 2002;62:3438–47.
44. Ramachandra M, Rahman A, Zou A, et al. Re-engineering adenovirus regulatory pathways to enhance oncolytic specificity and efficacy. *Nat Biotechnol* 2001;19:1035–41.
 45. Huang TG, Savontaus MJ, Shinozaki K, Sauter BV, Woo SL. Telomerase-dependent oncolytic adenovirus for cancer treatment. *Gene Ther* 2003;10:1241–7.
 46. Post DE, Van Meir EG. A novel hypoxia-inducible factor (HIF) activated oncolytic adenovirus for cancer therapy. *Oncogene* 2003;22:2065–72.
 47. Cuevas Y, Hernandez-Alcoceba R, Aragonés J, et al. Specific oncolytic effect of a new hypoxia-inducible factor-dependent replicative adenovirus on von Hippel-Lindau-defective renal cell carcinomas. *Cancer Res* 2003;63:6877–84.
 48. Markert JM, Medlock MD, Rabkin SD, et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. *Gene Ther* 2000;7:867–74.
 49. Varghese S, Rabkin SD. Oncolytic herpes simplex virus vectors for cancer virotherapy. *Cancer Gene Ther* 2002;9:967–78.
 50. Shen Y, Kitzes G, Nye JA, Fattaey A, Hermiston T. Analyses of single-amino-acid substitution mutants of adenovirus type 5 E1B–55K protein. *J Virol* 2001;75:4297–307.
 51. Lichtenstein DL, Toth K, Doronin K, Tollefson AE, Wold WS. Functions and mechanisms of action of the adenovirus E3 proteins. *Int Rev Immunol* 2004;23:75–111.
 52. Wang Y, Hallden G, Hill R, Anand A, et al. E3 gene manipulations affect oncolytic adenovirus activity in immunocompetent tumor models. *Nat Biotechnol* 2003;21:1328–35.
 53. Bergelson JM, Cunningham JA, Droguett G, et al. Isolation of a common receptor for Coxsackie B viruses and adenoviruses 2 and 5. *Science (Wash DC)* 1997;275:1320–3.
 54. Fechner H, Haack A, Wang H, et al. Expression of coxsackie adenovirus receptor and alphav-integrin does not correlate with adenovector targeting in vivo indicating anatomical vector barriers. *Gene Ther* 1999;6:1520–35.
 55. Tomko RP, Johansson CB, Totrov M, Abagyan R, Frisen J, Philipson L. Expression of the adenovirus receptor and its interaction with the fiber knob. *Exp Cell Res* 2000;255:47–55.
 56. Tomko RP, Xu R, Philipson L. HCAR and MCAR: the human and mouse cellular receptors for subgroup C adenoviruses and group B coxsackieviruses. *Proc Natl Acad Sci USA* 1997;94:3352–6.
 57. Dmitriev I, Krasnykh V, Miller CR, et al. An adenovirus vector with genetically modified fibers demonstrates expanded tropism via utilization of a coxsackievirus and adenovirus receptor-independent cell entry mechanism. *J Virol* 1998;72:9706–13.
 58. Hemmi S, Geertsens R, Mezzacasa A, Peter I, Dummer R. The presence of human coxsackievirus and adenovirus receptor is associated with efficient adenovirus-mediated transgene expression in human melanoma cell cultures. *Hum Gene Ther* 1998;9:2363–73.
 59. Miller CR, Buchsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. *Cancer Res* 1998;58:5738–48.
 60. Li Y, Pong RC, Bergelson JM, et al. Loss of adenoviral receptor expression in human bladder cancer cells: a potential impact on the efficacy of gene therapy. *Cancer Res* 1999;59:325–30.
 61. Fechner H, Wang X, Wang H, et al. Trans-complementation of vector replication versus Coxsackie-adenovirus-receptor overexpression to improve transgene expression in poorly permissive cancer cells. *Gene Ther* 2000;7:1954–68.
 62. Cripe TP, Dunphy EJ, Holub AD, et al. Fiber knob modifications overcome low, heterogeneous expression of the coxsackievirus-adenovirus receptor that limits adenovirus gene transfer and oncolysis for human rhabdomyosarcoma cells. *Cancer Res* 2001;61:2953–60.
 63. Haviv YS, Blackwell JL, Kanerva A, et al. Adenoviral gene therapy for renal cancer requires retargeting to alternative cellular receptors. *Cancer Res* 2002;62:4273–81.
 64. Rauen KA, Sudilovsky D, Le JL, et al. Expression of the coxsackie adenovirus receptor in normal prostate and in primary and metastatic prostate carcinoma: potential relevance to gene therapy. *Cancer Res* 2002;62:3812–8.
 65. Jee YS, Lee SG, Lee JC, et al. Reduced expression of coxsackievirus and adenovirus receptor (CAR) in tumor tissue compared to normal epithelium in head and neck squamous cell carcinoma patients. *Anti-cancer Res* 2002;22:2629–34.
 66. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiangioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. *J Natl Cancer Inst (Bethesda)* 2003;95:652–60.
 67. Yoshida Y, Sadata A, Zhang W, Saito K, Shinoura N, Hamada H. Generation of fiber-mutant recombinant adenoviruses for gene therapy of malignant glioma. *Hum Gene Ther* 1998;9:2503–15.
 68. Shinoura N, Yoshida Y, Tsunoda R, et al. Highly augmented cytopathic effect of a fiber-mutant E1B-defective adenovirus for gene therapy of gliomas. *Cancer Res* 1999;59:3411–6.
 69. Fisher KD, Stallwood Y, Green NK, Ulbrich K, Mautner V, Seymour LW. Polymer-coated adenovirus permits efficient retargeting and evades neutralising antibodies. *Gene Ther* 2001;8:341–8.
 70. Kirm D, Martuza RL, Zwiebel J. Replication-selective virotherapy for cancer: biological principles, risk management and future directions. *Nat Med* 2001;7:781–7.
 71. Nemunaitis J, Cunningham C, Buchanan A, et al. Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity. *Gene Ther* 2001;8:746–59.
 72. Reid T, Galanis E, Abbruzzese J, et al. Hepatic arterial infusion of a replication-selective oncolytic adenovirus (dl1520): phase II viral, immunologic, and clinical endpoints. *Cancer Res* 2002;62:6070–9.
 73. Marshall E. Gene therapy death prompts review of adenovirus vector. *Science (Wash DC)* 1999;286:2244–5.
 74. Nemunaitis J, Ganly I, Khuri F, et al. Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B–55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial. *Cancer Res* 2000;60:6359–66.
 75. Nemunaitis J, Khuri F, Ganly I, et al. Phase II trial of intratumoral administration of ONYX-015, a replication-selective adenovirus, in patients with refractory head and neck cancer. *J Clin Oncol* 2001;19:289–98.
 76. Demers GW, Johnson DE, Tsai V, et al. Pharmacologic indicators of antitumor efficacy for oncolytic virotherapy. *Cancer Res* 2003;63:4003–8.
 77. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. *Cancer Cell* 2003;4:7–11.
 78. Khuri FR, Nemunaitis J, Ganly I, et al. A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. *Nat Med* 2000;6:879–85.
 79. Lamont JP, Nemunaitis J, Kuhn JA, Landers SA, McCarty TM. A prospective phase II trial of ONYX-015 adenovirus and chemotherapy in recurrent squamous cell carcinoma of the head and neck (the Baylor experience). *Ann Surg Oncol* 2000;7:588–92.
 80. Kirm D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? *Gene Ther* 2001;8:89–98.
 81. Yu DC, Chen Y, Dilley J, et al. Antitumor synergy of CV787, a prostate cancer-specific adenovirus, and paclitaxel and docetaxel. *Cancer Res* 2001;61:517–25.
 82. Georger B, Grill J, Opolon P, et al. Potentiation of radiation therapy by the oncolytic adenovirus dl1520 (ONYX-015) in human malignant glioma xenografts. *Br J Cancer* 2003;89:577–84.
 83. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. *J Gene Med* 2000;2:148–64.

84. Wildner O, Blaese RM, Morris JC. Therapy of colon cancer with oncolytic adenovirus is enhanced by the addition of herpes simplex virus-thymidine kinase. *Cancer Res* 1999;59:410–3.
85. Freytag SO, Stricker H, Pegg J, et al. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer. *Cancer Res* 2003;63:7497–506.
86. Lamfers ML, Grill J, Dirven CM, et al. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. *Cancer Res* 2002;62:5736–42.
87. Chen Y, DeWeese T, Dilley J, et al. CV706, a prostate cancer-specific adenovirus variant, in combination with radiotherapy produces synergistic antitumor efficacy without increasing toxicity. *Cancer Res* 2001;61:5453–60.
88. Wildner O, Morris JC, Vahanian NN, Ford H, Jr, Ramsey WJ, Blaese RM. Adenoviral vectors capable of replication improve the efficacy of HSVtk/GCV suicide gene therapy of cancer. *Gene Ther* 1999;6:57–62.
89. Nanda D, Vogels R, Havenga M, Avezaat CJ, Bout A, Smitt PS. Treatment of malignant gliomas with a replicating adenoviral vector expressing herpes simplex virus-thymidine kinase. *Cancer Res* 2001;61:8743–50.
90. Wildner O, Morris JC. The role of the E1B 55 kDa gene product in oncolytic adenoviral vectors expressing herpes simplex virus-tk: assessment of antitumor efficacy and toxicity. *Cancer Res* 2000;60:4167–74.
91. Wildner O, Morris JC. Therapy of peritoneal carcinomatosis from colon cancer with oncolytic adenoviruses. *J Gene Med* 2000;2:353–60.
92. Lambright ES, Amin K, Wiewrodt R, et al. Inclusion of the herpes simplex thymidine kinase gene in a replicating adenovirus does not augment antitumor efficacy. *Gene Ther* 2001;8:946–53.
93. Aghi M, Chou TC, Suling K, Breakefield XO, Chiocca EA. Multimodal cancer treatment mediated by a replicating oncolytic virus that delivers the oxazaphosphorine/rat cytochrome P450 2B1 and ganciclovir/herpes simplex virus thymidine kinase gene therapies. *Cancer Res* 1999;59:3861–5.
94. Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene, and radiotherapy. *Hum Gene Ther* 1998;9:1323–33.
95. Rogulski KR, Wing MS, Paielli DL, Gilbert JD, Kim JH, Freytag SO. Double suicide gene therapy augments the antitumor activity of a replication-competent lytic adenovirus through enhanced cytotoxicity and radiosensitization. *Hum Gene Ther* 2000;11:67–76.
96. Freytag SO, Khil M, Stricker H, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. *Cancer Res* 2002;62:4968–76.
97. Stubdal H, Perin N, Lemmon M, et al. A prodrug strategy using ONYX-015-based replicating adenovirus to deliver rabbit carboxylesterase to tumor cells for conversion of CPT-11 to SN-38. *Cancer Res* 2003;63:6900–8.
98. Zhang JF, Hu C, Geng Y, Selm J, Klein SB, Orazi A, Taylor MW. Treatment of a human breast cancer xenograft with an adenovirus vector containing an interferon gene results in rapid regression due to viral oncolysis and gene therapy. *Proc Natl Acad Sci USA* 1996;93:4513–8.
99. Todryk SM, Gough MJ, Pockley AG. Facets of heat shock protein 70 show immunotherapeutic potential. *Immunology* 2003;110:1–9.
100. Huang XF, Ren W, Rollins L, et al. A broadly applicable, personalized heat shock protein-mediated oncolytic tumor vaccine. *Cancer Res* 2003;63:7321–9.
101. Dix BR, O'Carroll SJ, Myers CJ, Edwards SJ, Braithwaite AW. Efficient induction of cell death by adenoviruses requires binding of E1B55k and p53. *Cancer Res* 2000;60:2666–72.
102. van Beusechem VW, van den Doel PB, Grill J, Pinedo HM, Gerritsen WR. Conditionally replicative adenovirus expressing p53 exhibits enhanced oncolytic potency. *Cancer Res* 2002;62:6165–71.
103. Mulvihill S, Warren R, Venook A, et al. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. *Gene Ther* 2001;8:308–15.
104. Vasey PA, Shulman LN, Campos S, et al. Phase I trial of intraperitoneal injection of the E1B-55-kd-gene-deleted adenovirus ONYX-015 (dl1520) given on days 1 through 5 every 3 weeks in patients with recurrent/refractory epithelial ovarian cancer. *J Clin Oncol* 2002;20:1562–9.
105. Habib NA, Sarraf CE, Mitry RR, et al. E1B-deleted adenovirus (dl1520) gene therapy for patients with primary and secondary liver tumors. *Hum Gene Ther* 2001;12:219–26.
106. Habib N, Salama H, Abd El Latif Abu Median A, et al. Clinical trial of E1B-deleted adenovirus (dl1520) gene therapy for hepatocellular carcinoma. *Cancer Gene Ther* 2002;9:254–9.
107. Reid T, Galanis E, Abbruzzese J, et al. Intra-arterial administration of a replication-selective adenovirus (dl1520) in patients with colorectal carcinoma metastatic to the liver: a phase I trial. *Gene Ther* 2001;8:1618–26.
108. Ganly I, Kirn D, Eckhardt G, et al. A phase I study of Onyx-015, an E1B attenuated adenovirus, administered intratumorally to patients with recurrent head and neck cancer. *Clin Cancer Res* 2000;6:798–806.
109. Rudin CM, Cohen EE, Papadimitrakopoulou VA, et al. An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia. *J Clin Oncol* 2003;21:4546–52.
110. Fabra A, Parada C, Vinyals A, et al. Intravascular injections of a conditional replicative adenovirus (ad118) prevent metastatic disease in human breast carcinoma xenografts. *Gene Ther* 2001;8:1627–34.
111. Wirth T, Zender L, Schulte B, et al. A telomerase-dependent conditionally replicating adenovirus for selective treatment of cancer. *Cancer Res* 2003;63:3181–8.
112. Jakubczak JL, Ryan P, Gorziglia M, et al. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy. *Cancer Res* 2003;63:1490–9.
113. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. *Cancer Res* 1999;59:4200–3.
114. Fuerer C, Iggo R. Adenoviruses with Tcf binding sites in multiple early promoters show enhanced selectivity for tumour cells with constitutive activation of the wnt signalling pathway. *Gene Ther* 2002;9:270–81.
115. Adachi Y, Reynolds PN, Yamamoto M, et al. A midkine promoter-based conditionally replicative adenovirus for treatment of pediatric solid tumors and bone marrow tumor purging. *Cancer Res* 2001;61:7882–8.
116. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. *Mol Ther* 2003;8:449–58.
117. Portella G, Scala S, Vitagliano D, Vecchio G, Fusco A. ONYX-015, an E1B gene-defective adenovirus, induces cell death in human anaplastic thyroid carcinoma cell lines. *J Clin Endocrinol Metab* 2002;87:2525–31.
118. You L, Yang CT, Jablons DM. ONYX-015 works synergistically with chemotherapy in lung cancer cell lines and primary cultures freshly made from lung cancer patients. *Cancer Res* 2000;60:1009–13.
119. Heise C, Lemmon M, Kirn D. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. *Clin Cancer Res* 2000;6:4908–14.
120. Portella G, Pacelli R, Libertini S, et al. ONYX-015 enhances radiation-induced death of human anaplastic thyroid carcinoma cells. *J Clin Endocrinol Metab* 2003;88:5027–32.